JP2024511836A - 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤 - Google Patents

膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤 Download PDF

Info

Publication number
JP2024511836A
JP2024511836A JP2023560325A JP2023560325A JP2024511836A JP 2024511836 A JP2024511836 A JP 2024511836A JP 2023560325 A JP2023560325 A JP 2023560325A JP 2023560325 A JP2023560325 A JP 2023560325A JP 2024511836 A JP2024511836 A JP 2024511836A
Authority
JP
Japan
Prior art keywords
compound
salt
treatment
pancreatic cancer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511836A5 (https=
Inventor
ゾーイ・ジョンソン
カロリーナ・ニボラ－スタシュコフスカ
ラース・ファン・デル・ヴィーン
ジョージア・コンスタンティニド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionctura SA
Original Assignee
Ionctura SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104416.9A external-priority patent/GB202104416D0/en
Priority claimed from GBGB2108242.5A external-priority patent/GB202108242D0/en
Priority claimed from GBGB2117511.2A external-priority patent/GB202117511D0/en
Application filed by Ionctura SA filed Critical Ionctura SA
Publication of JP2024511836A publication Critical patent/JP2024511836A/ja
Publication of JP2024511836A5 publication Critical patent/JP2024511836A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023560325A 2021-03-29 2022-03-29 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤 Pending JP2024511836A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2104416.9A GB202104416D0 (en) 2021-03-29 2021-03-29 Treatment reginmens
GB2104416.9 2021-03-29
GB2108242.5 2021-06-09
GBGB2108242.5A GB202108242D0 (en) 2021-06-09 2021-06-09 Methods of treatment
GBGB2117511.2A GB202117511D0 (en) 2021-12-03 2021-12-03 Treatment regimens
GB2117511.2 2021-12-03
PCT/EP2022/058296 WO2022207648A1 (en) 2021-03-29 2022-03-29 A pi3k-delta inhibitor for the treatment of pancreatic cancer

Publications (2)

Publication Number Publication Date
JP2024511836A true JP2024511836A (ja) 2024-03-15
JP2024511836A5 JP2024511836A5 (https=) 2025-04-04

Family

ID=81388891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560325A Pending JP2024511836A (ja) 2021-03-29 2022-03-29 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤

Country Status (7)

Country Link
US (1) US20240216385A1 (https=)
EP (1) EP4313059A1 (https=)
JP (1) JP2024511836A (https=)
AU (1) AU2022250707B2 (https=)
CA (1) CA3212522A1 (https=)
MX (1) MX2023011441A (https=)
WO (1) WO2022207648A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024522135A (ja) * 2021-06-09 2024-06-11 アイオンクチュラ・ベー・フェー 膵臓癌の治療のためのオートタキシン（ａｔｘ）阻害剤

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202308807D0 (en) * 2023-06-13 2023-07-26 Ionctura Sa Combinations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510825A (ja) * 2009-11-13 2013-03-28 メルク セローノ ソシエテ アノニム 三環式ピラゾールアミン誘導体
WO2014121901A1 (en) * 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms
JP2018508498A (ja) * 2015-02-06 2018-03-29 キャンサー・リサーチ・テクノロジー・リミテッド オートタキシン阻害化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9986723B2 (en) * 2014-10-22 2018-06-05 The Board Of Regents Of The University Of Texas System Screen and use of therapeutics for pancreatic ductal adenocarcinoma
EP3610264A1 (en) * 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510825A (ja) * 2009-11-13 2013-03-28 メルク セローノ ソシエテ アノニム 三環式ピラゾールアミン誘導体
WO2014121901A1 (en) * 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms
JP2018508498A (ja) * 2015-02-06 2018-03-29 キャンサー・リサーチ・テクノロジー・リミテッド オートタキシン阻害化合物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AMY R. MACQUEEN ET AL.: "Abstract 666: A novel, highly selective PI3Kδ inhibitor for the treatment of solid malignancies tha", CANCER RES, vol. 80巻16_Supplement号, JPN7026000971, 15 August 2020 (2020-08-15), pages 666, ISSN: 0005810817 *
ERKUT BORAZANCI ET AL.: "A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy", THE ONCOLOGIST, vol. 25巻11号, JPN7026000970, 28 June 2020 (2020-06-28), pages 1604 - 1613, ISSN: 0005810816 *
FRANCESCA R. AUCIELLO ET AL.: "A stromal lysolipid-autotaxin signaling axis promotes pancreatic tumor progression", CANCER DISCOV, vol. 9巻5号, JPN7026000973, 1 May 2019 (2019-05-01), pages 617 - 627, ISSN: 0005810819 *
FRONTIERS IN IMMUNOLOGY, vol. 5, no. 233, JPN6026009083, 2014, pages 1 - 15, ISSN: 0005810814 *
KATHERINE EWINGS ET AL.: "Preclinical development of a novel, highlyselective PI3Kδ inhibitor, IOA-244, for the treatment ofs", CANCER RES, vol. 79巻13_Supplement号, JPN7026000972, 1 July 2019 (2019-07-01), pages 2692, ISSN: 0005810818 *
NATURE, vol. 510, JPN6026009084, 2014, pages 407 - 411, ISSN: 0005810815 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024522135A (ja) * 2021-06-09 2024-06-11 アイオンクチュラ・ベー・フェー 膵臓癌の治療のためのオートタキシン（ａｔｘ）阻害剤

Also Published As

Publication number Publication date
MX2023011441A (es) 2023-10-18
AU2022250707B2 (en) 2026-04-09
WO2022207648A1 (en) 2022-10-06
US20240216385A1 (en) 2024-07-04
AU2022250707A1 (en) 2023-10-12
CA3212522A1 (en) 2022-10-06
EP4313059A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
US11266654B2 (en) Apilimod compositions and methods for using same
EP3325014B1 (en) Methods for treating cancer using apilimod
RU2607596C2 (ru) Комбинированная противораковая терапия
US20180078561A1 (en) Active metabolites of apilimod and uses thereof
JP2024511836A (ja) 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤
KR20240158972A (ko) 소세포 폐암의 치료 방법
CN116997340A (zh) 用于治疗胰腺癌的PI3K-δ抑制剂
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
HK1254258B (en) Methods for treating cancer using apilimod
HK1226329B (en) Apilimod compositions for treating non-hodgkin's b cell lymphoma
NZ722491B2 (en) Apilimod compositions and methods for using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250326

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260305